Cellectis SA (NASDAQ: CLLS) Starts Presentation at 29th Annual ROTH Conference
Cellectis (NASDAQ: CLLS) is a biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART). The company is engaged in developing a new generation of cancer therapies based on engineered T-cells. Cellectis capitalizes on its 17 years of experience in genome engineering based on its flagship TALEN® products and meganucleases as well as its pioneering electroporation PulseAgile technology, to create a new generation of immunotherapies. Using its life-science-focused, pioneering genome-engineering technologies, Cellectis’ goal is to create innovative products in multiple fields and with various target markets. For more information, visit the company’s website at www.cellectis.com. About NetworkNewsWire NetworkNewsWire…
